These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10516375)

  • 1. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit.
    Macdougall IC; Chandler G; Elston O; Harchowal J
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S40-6. PubMed ID: 10516375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
    Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
    Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of iron indices in hemodialysis patients receiving epoetin.
    Kaufman JS; Reda DJ; Fye CL; Goldfarb DS; Henderson WG; Kleinman JG; Vaamonde CA;
    Kidney Int; 2001 Jul; 60(1):300-8. PubMed ID: 11422765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
    Pollak VE; Lorch JA; Shukla R; Satwah S
    BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
    Pizzi LT; Bunz TJ; Coyne DW; Goldfarb DS; Singh AK
    Kidney Int; 2008 Dec; 74(12):1588-95. PubMed ID: 19034302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
    Pizzarelli F; David S; Sala P; Icardi A; Casani A
    Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
    Roger SD; Cooper B
    Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost savings using a protocol approach to manage anemia in a hemodialysis unit.
    Charlesworth EC; Richardson RM; Battistella M
    Am J Nephrol; 2014; 39(6):509-14. PubMed ID: 24903565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients.
    Leikis MJ; Kent AB; Becker GJ; McMahon LP
    Nephrology (Carlton); 2004 Jun; 9(3):153-60. PubMed ID: 15189176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. National perspective on iron therapy as a clinical performance measure for maintenance hemodialysis patients.
    Owen WF; Szczech L; Johnson C; Frankenfield D
    Am J Kidney Dis; 1999 Oct; 34(4 Suppl 2):S5-S11. PubMed ID: 10516369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous compared with intravenous epoetin treatment in patients on hemodialysis: one center study.
    Malovrh M; Premru V
    Ther Apher Dial; 2005 Jun; 9(3):233-6. PubMed ID: 15966996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term intravenous epoetin-alpha / darbepoetin-alpha ratio in iron-replete hemodialysis patients.
    Icardi A; Sacco P; Salvatore F; Romano U
    J Nephrol; 2007; 20(1):73-9. PubMed ID: 17347977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
    Taylor JE; Peat N; Porter C; Morgan AG
    Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of RBC ferritin and reticulocyte measurements in monitoring response to intravenous iron therapy.
    Bhandari S; Norfolk D; Brownjohn A; Turney J
    Am J Kidney Dis; 1997 Dec; 30(6):814-21. PubMed ID: 9398126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anemia management of adult hemodialysis patients in the US results: from the 1997 ESRD Core Indicators Project.
    Frankenfield D; Johnson CA; Wish JB; Rocco MV; Madore F; Owen WF
    Kidney Int; 2000 Feb; 57(2):578-89. PubMed ID: 10652035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
    Attallah N; Osman-Malik Y; Frinak S; Besarab A
    Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.